My ePortfolio Register   

Temporary ovarian suppression with hormone analogue may preserve fertility during breast cancer chemotherapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.17
Views: 120

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium

Dr Lambertini speaks at a SABCS 2017 press session about a meta-analysis of individual patient data from five randomised clinical trials provided a high level of evidence that treatment with a gonadotropin-releasing hormone analog (GnRHa) could safely and effectively protect ovarian function, and potentially preserve fertility in premenopausal women receiving chemotherapy for early-stage breast cancer.

Read the news story for more.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence